Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of Fiscal 2020
January 13, 2021 at 09:30 pm
Share
Ekso Bionics Holdings, Inc. provided revenue guidance for the fourth quarter and full year of fiscal 2020. Total revenue for the fourth quarter of 2020 is estimated to be $2.3 million, compared to total revenue of $3.7 million in the fourth quarter of 2019.
Total revenue for fiscal year 2020 is estimated to be approximately $8.9 million, compared to $13.9 million in 2019.
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.